CEO interview in BioStock

January 7, 2020
Language flag
HoloMonitor M4 with logo

In the article published today by BioStock, the company's CEO Peter Egelberg comments on National Institutes of Health and the developments during the past autumn. The article (in Swedish) is available here.

Latest News

Biostock-PHI-on-how-TO-3-proceeds-will-be-used

BioStock: PHI on how TO 3 proceeds will be used

BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.

Last day of trading in warrants of series TO 3 is 27 April 2023

Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with PHI’s rights issue of units that was announced on 22 February 2022. The exercise period runs until and including 2 May 2023.

Insider Acquisitions in Phase Holographic Imaging

CEO Patrik Eschricht, chairman Peter Egelberg and deputy board member Ann Christine Egelberg has recently acquired additional holdings in Phase Holographic Imaging.
See All News